Mirum Pharmaceuticals reports 59% response rate in AZURE-4 Phase 3 study of brelovitug for HDV, significantly outperforming the delayed-treatment arm's 0% rate.
Mirum Pharmaceuticals announced positive Phase 3 results for LIVMARLI, achieving 1.81-point pruritus improvement. A supplemental NDA is targeted for early 2027.
Mirum Pharmaceuticals, Inc. · · 4 min read
Track Mirum Pharmaceuticals, Inc. live
Get the next Mirum Pharmaceuticals, Inc. SEC filing seconds after it lands.